Age-related macular degeneration (AMD) and myopic maculopathy are leading causes of irreversible vision loss in developed countries. Not only is long-distance visual acuity affected, but reduced near visual acuity remains a significant problem for individuals with these pathologies. External magnifying low-vision aids are available; however, their use is often uncomfortable and has a limited acceptance rate [1]. Various intraocular lenses (IOLs) or telescopic systems have been developed, but they have not been widely accepted due to insufficient magnification, difficult surgical procedures, high complication rates, high costs, and negative effects on distance visual acuity and/or visual field. Most solutions require a phakic status of the eye and are implanted during cataract surgery [2]. The Scharioth Macula Lens (SML, Medicontur) is a magnifying intraocular lens designed for pseudophakic patients. The SML is implanted in the ciliary sulcus of one eye, providing a mathematically calculated average two-fold magnification. The peripheral zone of the lens is optically neutral, with other dioptric powers available. Additionally, the lens has polished round edges on the optic to reduce photic phenomena (Fig. 1) [3]. Implantation of the SML has been shown to improve the near visual acuity of pseudophakic patients with stable AMD or myopic maculopathy, without impairing distance visual acuity [3], [4], [5]. To date, no studies have been conducted with a follow-up period longer than one year after SML implantation.

The objective of this case series is to present the visual acuity and quality of life results of these patients with a three-year follow-up.